A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05936151 · Completed

Last updated 2026-05-28

This study is testing the effects of the medication retatrutide on kidney function in adults who have overweight or obesity, chronic kidney disease, and may or may not have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 146 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-07 · est. completion 2025-10

Where 42 sites · Canada, Italy, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT05936151 ↗

Description as written by the study sponsor.

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in Glomerular Filtration Rate (mGFR)
Sponsor	Eli Lilly and Company
Conditions studied	Overweight or Obesity, CKD, Type 2 Diabetes
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05936151 ↗